<DOC>
	<DOCNO>NCT01580579</DOCNO>
	<brief_summary>Lung cancer [ LC ] lead cause cancer death worldwide . The standard treatment locally advanced lung cancer unresectable marginally resectable combination therapy radical preoperative chemoradiation . The local control rate survival treatment modality increase 30 % . Radiotherapy [ RT ] technical mold 3D [ 3D-CRT , Three-Dimensional Conformal Radiation Therapy ] IMRT [ intensity-modulated radiation therapy ] allow total dose radiation increase lead direct benefit result treatment . Between 17-30 % patient susceptible pneumonitis due radiation [ NR ] . This complication may appear end RT 6 month treatment . In severe case , mortality reach 50 % . It 's well know various disease , functional abnormality precede clinical manifestation . The degree pulmonary failure secondary RT measure follow standard Radiation Therapy Oncology Group rank degree [ 0 4 ] . Not precisely know factor influence development NR .</brief_summary>
	<brief_title>Predictors Radiation Pneumonitis Locally Advanced Lung Cancer Treated With Chemoradiation</brief_title>
	<detailed_description>Objectives : To evaluate effect chemotherapy thoracic radiotherapy pulmonary function identify predictor radiation pneumonitis locally advanced lung cancer [ stag IIIA IIIB ] . Hypothesis : Respiratory function test may predict development radiation pneumonitis patient locally advanced lung cancer receive radical treatment chemoradiation . Methods Prospective cohort study patient locally advanced lung cancer Lung Cancer Clinic National Cancer Institute [ INCAN ] . Patients receive weekly paclitaxel 50 mg carboplatin AUC 2 concomitant radiotherapy 44-63 Gy ( 22-33 fraction ) . Followup lung function test baseline , treatment radiotherapy carry 4 occasion .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Radiation Pneumonitis</mesh_term>
	<criteria>Candidates must understand sign informed consent Histopathological diagnosis locally advanced lung cancer [ IIIAcT2N12 , cT3N12 , cT4N0 , M0o IIIB : cT2N3 , cT3N3 , cT4N13 , M0 ] . They may also include patient oligometastatic disease [ M1 ] candidate chemoradiation Any histology Medical test : white blood cell count ≥ plasma 3,000 / mm3 , platelet ≥ 100,000 / mm 3 , hemoglobin ≥ 12 g / dl , serum creatinine ≤ 1.5 mg / dl , total bilirubin ≤ 1.5 , transaminase [ ≤ 2.5 time upper limit normal [ ULN ] , alkaline phosphatase &lt; 5 ULN . Age ≥ 18 year . General condition score accord ECOG 0 2 ≥ 60 % Karnofsky . Estimated life expectancy treatment least 24 week . Exclusion criterion : Uncontrolled concurrent disease . History previous radiotherapy primary site . Pregnant breastfeeding . Use anticoagulants therapeutic dos Intercurrent Malignancies , except dormant basal cell carcinoma skin , carcinoma situ cervix Invasive cancer unless background least 5 year diseasefree status .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiation pneumonitis</keyword>
	<keyword>locally advanced lung cancer</keyword>
	<keyword>Respiratory function test</keyword>
</DOC>